{
    "id": 25849,
    "fullName": "CD22 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD22 positive indicates the presence of the CD22 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 933,
        "geneSymbol": "CD22",
        "terms": [
            "CD22",
            "SIGLEC-2",
            "SIGLEC2"
        ]
    },
    "variant": "positive",
    "createDate": "01/03/2017",
    "updateDate": "08/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15347,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ADCT-602 (hLL2-cys-PBD) demonstrated cytotoxicity in several CD22-expressing lymphoma cell lines in culture, and induced tumor regression in CD22-expressing lymphoma xenograft models (Blood 2016 128:4176).",
            "molecularProfile": {
                "id": 26964,
                "profileName": "CD22 positive"
            },
            "therapy": {
                "id": 7565,
                "therapyName": "ADCT-602",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13101,
                    "pubMedId": null,
                    "title": "hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.",
                    "url": "http://www.bloodjournal.org/content/128/22/4176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26964,
            "profileName": "CD22 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}